Still A Chance For Broad Use Of Teva's Reslizumab?
This article was originally published in Scrip
Executive Summary
The FDA's Pulmonary-Allergy Drugs Advisory Committee on Dec. 9 threw its support behind Teva Pharmaceutical Industries Ltd.'s experimental asthma drug reslizumab as a treatment for adults with severe asthma, but said there were not enough data about whether the drug is safe and effective in adolescents 12-17 years.